{
  "products": [
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 1,
      "product_code": "BI 1015550",
      "product_name": "Nerandomilast",
      "product_type": "NCE",
      "base_technology": "Twin Screw Granulation (TSG)",
      "mechanism_of_action": "A first-in-class preferential PDE4B inhibitor aiming to halt disease progression in Idiopathic Pulmonary Fibrosis (IPF). It has a BCS-IV classification, complicating formulation.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Respiratory",
      "current_phase": "Registration",
      "project_status": "On Track",
      "lead_indication": "Idiopathic Pulmonary Fibrosis (IPF)",
      "expected_launch_year": 2025,
      "lifecycle_indications": [
        {
          "phase": "Phase 3",
          "indication": "Progressive Pulmonary Fibrosis (PPF)"
        },
        {
          "phase": "Phase 2",
          "indication": "Systemic Sclerosis (SSc)"
        },
        {
          "phase": "Pre-Clinical",
          "indication": "Pediatric (PF-ILD)"
        }
      ],
      "regulatory_designations": [
        "Breakthrough Therapy Designation",
        "Orphan Drug Designation"
      ],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "ING_SoL",
          "Koropi"
        ],
        "DS": [
          "ING"
        ]
      },
      "volume_forecast": {
        "DP": "Medium (10 - 100 million PCS)",
        "DS": "Low (10 - 1,000 kg)"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 2,
      "product_code": "BI 1810631",
      "product_name": "Zongertinib",
      "product_type": "NCE",
      "base_technology": "Roller Compaction & Organic Spray Drying",
      "mechanism_of_action": "An irreversible, selective HER2 kinase inhibitor for previously treated (2L) Non-Small Cell Lung Cancer (NSCLC) with HER2 mutations. As a covalent inhibitor, it presents unique stability challenges.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Oncology",
      "current_phase": "Registration",
      "project_status": "At Risk",
      "lead_indication": "Non-Small Cell Lung Cancer (NSCLC) (2L)",
      "expected_launch_year": 2025,
      "lifecycle_indications": [
        {
          "phase": "Phase 3",
          "indication": "NSCLC (1L)"
        },
        {
          "phase": "Phase 1",
          "indication": "Breast Cancer (1L & 3L+)"
        },
        {
          "phase": "Phase 1",
          "indication": "Gastric Cancer (2L)"
        }
      ],
      "regulatory_designations": [
        "Breakthrough Therapy Designation",
        "Fast Track Designation"
      ],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "Hovione",
          "ING"
        ],
        "DS": [
          "Cambrex",
          "Alphora"
        ]
      },
      "volume_forecast": {
        "DP": "Low (1 - 10 million PCS)",
        "DS": "Low (10 - 1,000 kg)"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 3,
      "product_code": "BI 456906",
      "product_name": "Survodutide",
      "product_type": "NBE",
      "base_technology": "Peptide",
      "mechanism_of_action": "A dual glucagon receptor (GCGR) and GLP-1 receptor (GLP1R) agonist peptide designed to leverage two key metabolic pathways for significant weight reduction.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Phase 3",
      "project_status": "Delayed",
      "lead_indication": "Obesity",
      "expected_launch_year": 2027,
      "lifecycle_indications": [
        {
          "phase": "Phase 3",
          "indication": "Metabolic dysfunction-associated steatohepatitis (MASH)"
        },
        {
          "phase": "Pre-Clinical",
          "indication": "Obesity PEN"
        },
        {
          "phase": "Phase 1",
          "indication": "BI 1820237 + Survodutide (Combo)"
        }
      ],
      "regulatory_designations": [
        "Breakthrough Therapy Designation",
        "Fast Track Designation"
      ],
      "manufacturing_strategy": "Hybrid",
      "manufacturing_sites": {
        "DP": [
          "LPC"
        ],
        "DS": [
          "PPG",
          "Thermo Fisher",
          "ING"
        ]
      },
      "volume_forecast": {
        "DP": "High",
        "DS": "High"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 4,
      "product_code": "BI 764532",
      "product_name": "Obrixtamig",
      "product_type": "NBE",
      "base_technology": "BI-HEX\u00ae Platform",
      "mechanism_of_action": "A T-cell engaging bispecific antibody, binding DLL3 on tumor cells and CD3 on T-cells to induce killing of neuroendocrine tumors.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Small Cell Lung Cancer (SCLC) (2L)",
      "expected_launch_year": 2028,
      "lifecycle_indications": [
        {
          "phase": "Phase 2",
          "indication": "Extra-pulmonary neuroendocrine carcinoma (epNEC)"
        },
        {
          "phase": "Discontinued",
          "indication": "3L SCLC"
        },
        {
          "phase": "Discontinued",
          "indication": "LC-NEC"
        },
        {
          "phase": "Discontinued",
          "indication": "LS SCLC"
        }
      ],
      "regulatory_designations": [
        "Breakthrough Therapy Designation",
        "Fast Track Designation"
      ],
      "manufacturing_strategy": "Hybrid",
      "manufacturing_sites": {
        "DP": [
          "Vetter"
        ],
        "DS": [
          "Vienna",
          "Biberach"
        ]
      },
      "volume_forecast": {
        "DP": "Low (1 - 10 million PCS)",
        "DS": "Very Low (< 5 12k runs)"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 5,
      "product_code": "BI 690517",
      "product_name": "Vicadrostat",
      "product_type": "NCE",
      "base_technology": "Twin Screw Granulation (TSG)",
      "mechanism_of_action": "A novel, selective, and potent aldosterone synthase inhibitor (ASi) used in combination with empagliflozin. Requires high-precision synthesis to maintain >300-fold selectivity.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Phase 3",
      "project_status": "On Track",
      "lead_indication": "Chronic Kidney Disease (CKD)",
      "expected_launch_year": 2028,
      "lifecycle_indications": [
        {
          "phase": "Phase 3",
          "indication": "Heart Failure with Preserved Ejection Fraction (HFpEF)"
        },
        {
          "phase": "Discontinued",
          "indication": "Untreated Hypertension (uHTN)"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "ING_SoL"
        ],
        "DS": [
          "ING"
        ]
      },
      "volume_forecast": {
        "DP": "High (>100M PCS)",
        "DS": "High (>10 tn)"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 6,
      "product_code": "BI 1291583",
      "product_name": "Cathepsin C Inhibitor",
      "product_type": "NCE",
      "base_technology": "Roller Compaction",
      "mechanism_of_action": "Blocks the Cathepsin C enzyme to prevent inflammatory protease activation. The powder blend has an extremely low minimum ignition energy (MIE <3 mJ), requiring inert atmospheres.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Respiratory",
      "current_phase": "Phase 2",
      "project_status": "Delayed",
      "lead_indication": "Bronchiectasis (BE)",
      "expected_launch_year": 2029,
      "lifecycle_indications": [
        {
          "phase": "Discontinued",
          "indication": "ANCA-Associated Vasculitis"
        },
        {
          "phase": "Discontinued",
          "indication": "Hidradenitis Suppurativa"
        },
        {
          "phase": "Pre-Clinical",
          "indication": "Pediatric (nCFB)"
        }
      ],
      "regulatory_designations": [
        "Fast Track Designation"
      ],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "ING_SoL"
        ],
        "DS": [
          "ING"
        ]
      },
      "volume_forecast": {
        "DP": "Medium (10 - 100 million PCS)",
        "DS": "Low (10 - 1,000 kg)"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 7,
      "product_code": "BI 3720931",
      "product_name": "CF Gene Therapy",
      "product_type": "NBE_NTM",
      "base_technology": "Viral Vector",
      "mechanism_of_action": "A third-generation Lentiviral vector pseudotyped with Sendai virus proteins to enable delivery of a functional CFTR gene via inhalation. Requires BSL-2+ Containment.",
      "dosage_form": "Inhalable",
      "therapeutic_area": "Respiratory",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Cystic Fibrosis (CF)",
      "expected_launch_year": 2031,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "Oxford BioMedica"
        ],
        "DS": [
          "Oxford BioMedica"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 8,
      "product_code": "BI 1831169",
      "product_name": "VSV-GP Oncolytic Virus",
      "product_type": "NBE_NTM",
      "base_technology": "Viral Vector",
      "mechanism_of_action": "A first-generation Oncolytic Virus where the native neurotropic glycoprotein is replaced to improve safety while retaining the ability to kill cancer cells. Requires BSL-2+ Containment.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Pancreatic Ductal Adenocarcinoma (PDAC)",
      "expected_launch_year": 2033,
      "lifecycle_indications": [
        {
          "phase": "Phase 1",
          "indication": "HNSCC"
        },
        {
          "phase": "Phase 1",
          "indication": "Melanoma"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "Lonza"
        ],
        "DS": [
          "Lonza"
        ]
      },
      "volume_forecast": {
        "DP": "Very Low (< 1 million PCS)",
        "DS": "High (> 30 12k runs)"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 9,
      "product_code": "BI 3940749",
      "product_name": "KRASmulti degrader",
      "product_type": "NBE_NTM",
      "base_technology": "PROTAC",
      "mechanism_of_action": "A PROTAC (Proteolysis Targeting Chimera) molecule designed to hijack the cell's natural disposal system to selectively destroy multiple forms of KRAS protein.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Oncology",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Colorectal Cancer (CRC)",
      "expected_launch_year": 2030,
      "lifecycle_indications": [
        {
          "phase": "Pre-Clinical",
          "indication": "NSCLC"
        },
        {
          "phase": "Pre-Clinical",
          "indication": "PDAC"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": "tbd",
        "DS": "tbd"
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 10,
      "product_code": "BI 3810539",
      "product_name": "DLL3 ADC",
      "product_type": "NBE_NTM",
      "base_technology": "Antibody-Drug Conjugate",
      "mechanism_of_action": "An Antibody-Drug Conjugate combining biologics manufacturing with HPAPI (cytotoxic payload) synthesis. It requires site-specific conjugation technologies and OEB4 containment.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Triple-Negative Breast Cancer (TNBC)",
      "expected_launch_year": 2033,
      "lifecycle_indications": [
        {
          "phase": "Pre-Clinical",
          "indication": "Small Cell Lung Cancer (SCLC)"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Hybrid",
      "manufacturing_sites": {
        "DP": "tbd",
        "DS": "Internal/Sutro"
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 11,
      "product_code": "T3P-Y058-739",
      "product_name": "YE-cGAS/RIG1",
      "product_type": "NBE_NTM",
      "base_technology": "Yeast-based Immunotherapy",
      "mechanism_of_action": "An engineered yeast-based immunotherapy designed to activate both the cGAS-STING and RIG-I innate immune pathways in tumors.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "expected_launch_year": 2031,
      "lifecycle_indications": [
        {
          "phase": "Phase 1",
          "indication": "Melanoma"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": "tbd",
        "DS": "tbd"
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 12,
      "product_code": "BI 764524",
      "product_name": "Anti-Sema3A AB",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "An antibody targeting Semaphorin-3A, a protein involved in vascular development, for treating retinal diseases.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Eye Health",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Diabetic Retinopathy (DR)",
      "expected_launch_year": 2031,
      "lifecycle_indications": [
        {
          "phase": "Pre-Clinical",
          "indication": "CI-DME"
        },
        {
          "phase": "Pre-Clinical",
          "indication": "iRVO"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "Vetter"
        ],
        "DS": [
          "Rentschler"
        ]
      },
      "volume_forecast": {
        "DP": "Very Low (< 1 million PCS)",
        "DS": "Very Low (< 5 12k runs)"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 13,
      "product_code": "BI 3797479",
      "product_name": "COMT Inhibitor",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "A small molecule designed to inhibit the COMT enzyme to treat cognitive impairment. Requires specialized containment and controlled atmosphere processing due to psychoactive properties.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Mental Health",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Cognitive Impairment Associated with Schizophrenia (CIAS)",
      "expected_launch_year": 2032,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": "tbd",
        "DS": "tbd"
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 14,
      "product_code": "BI 771716",
      "product_name": "Anti-C3 AB",
      "product_type": "NBE",
      "base_technology": "Microbial",
      "mechanism_of_action": "An antibody fragment that inhibits C3, a central component of the complement cascade, to prevent the inflammation and cell death that drive Geographic Atrophy.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Eye Health",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Geographic Atrophy (GA)",
      "expected_launch_year": 2030,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "Biberach"
        ],
        "DS": [
          "Fremont"
        ]
      },
      "volume_forecast": {
        "DP": "Very Low (< 1 million PCS)",
        "DS": "Low (6 - 15 12k runs)"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 15,
      "product_code": "BI 754089",
      "product_name": "Ezabenlimab",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "A foundational PD-1 antibody that blocks the PD-1/PD-L1 pathway, releasing the brakes on the immune system to allow T-cells to attack cancer cells.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Solid Tumors (as combination backbone)",
      "expected_launch_year": null,
      "lifecycle_indications": [
        {
          "phase": "Phase 1",
          "indication": "Immunology"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Hybrid",
      "manufacturing_sites": {
        "DP": [
          "Biberach"
        ],
        "DS": [
          "Fremont"
        ]
      },
      "volume_forecast": {
        "DP": "Low (1 - 10 million PCS)",
        "DS": "Low (6 - 15 12k runs)"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 16,
      "product_code": "BI 3797363",
      "product_name": "STING inhibitor",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "A small molecule designed to inhibit the STING pathway in autoimmune diseases. Requires HPAPI (High-Potency Active Pharmaceutical Ingredient) Handling.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Immunology",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Systemic Sclerosis (SSc)",
      "expected_launch_year": null,
      "lifecycle_indications": [
        {
          "phase": "Pre-Clinical",
          "indication": "Interferonopathies (IFN)"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": "tbd",
        "DS": "tbd"
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 17,
      "product_code": "Spesolimab_HS",
      "product_name": "Spesolimab (HS indication)",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "Anti-IL36R antibody. A monoclonal antibody designed to block the IL-36 receptor, a key driver of inflammation.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Immunology",
      "current_phase": "Discontinued",
      "project_status": "Delayed",
      "lead_indication": "Hidradenitis Suppurativa (HS)",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": "Internal",
        "DS": "Internal BI-HEX Platform"
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 18,
      "product_code": "Iclepertin",
      "product_name": "Iclepertin",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "GLYT1 inhibitor. Designed to enhance NMDA receptor function to treat Cognitive Impairment Associated with Schizophrenia (CIAS).",
      "dosage_form": "Tablet",
      "therapeutic_area": "Mental Health",
      "current_phase": "Discontinued",
      "project_status": "Delayed",
      "lead_indication": "Cognitive Impairment Associated with Schizophrenia (CIAS)",
      "expected_launch_year": null,
      "lifecycle_indications": [
        {
          "phase": "Discontinued",
          "indication": "CIAS (Long-Acting Injectable)"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": "Internal",
        "DS": "Internal"
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:33:09.768379+00:00",
      "updated_at": "2025-07-15 19:33:09.768379+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 19,
      "product_code": "BI 1821736",
      "product_name": "VSV-GP-CD80-Fc OV",
      "product_type": "NBE_NTM",
      "base_technology": "Viral Vector",
      "mechanism_of_action": "Second-generation oncolytic virus (Vesicular Stomatitis Virus) with enhanced immune-stimulatory properties via the CD80-Fc component. Requires BSL-2+ Containment.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Phase 1",
      "project_status": "At Risk",
      "lead_indication": "Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "expected_launch_year": 2030,
      "lifecycle_indications": [
        {
          "phase": "Phase 1",
          "indication": "Melanoma"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "Lonza"
        ],
        "DS": [
          "Lonza"
        ]
      },
      "volume_forecast": {
        "DP": "Very Low (< 1 million PCS)",
        "DS": "High (> 30 12k runs)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 20,
      "product_code": "BI 3923948",
      "product_name": "VSV-GP-GSDME-IL12",
      "product_type": "NBE_NTM",
      "base_technology": "Viral Vector",
      "mechanism_of_action": "An oncolytic virus engineered with Gasdermin E (GSDME) to induce inflammatory cell death (pyroptosis) and IL-12 to stimulate a strong immune response. Requires BSL-2+ Containment.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Triple-Negative Breast Cancer (TNBC)",
      "expected_launch_year": 2034,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 21,
      "product_code": "BI 3009947",
      "product_name": "STING inhibitor",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "A small molecule designed to inhibit the STING pathway for treating autoimmune conditions. Requires HPAPI handling.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Immunology",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Systemic Sclerosis (SSc)",
      "expected_launch_year": null,
      "lifecycle_indications": [
        {
          "phase": "Pre-Clinical",
          "indication": "Interferonopathies (IFN)"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 22,
      "product_code": "BI 1569912",
      "product_name": "NR2B NAM",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "A selective NMDA receptor subunit 2b (NR2B) negative allosteric modulator (NAM) being investigated as an adjunctive therapy for Major Depressive Disorder (MDD).",
      "dosage_form": "Tablet",
      "therapeutic_area": "Mental Health",
      "current_phase": "Phase 2",
      "project_status": "Accelerated",
      "lead_indication": "Major Depressive Disorder (MDD) - adjunctive",
      "expected_launch_year": 2028,
      "lifecycle_indications": [
        {
          "phase": "Phase 2",
          "indication": "MDD - monotherapy"
        },
        {
          "phase": "Pre-Clinical",
          "indication": "Bipolar depression"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "ING"
        ],
        "DS": [
          "ING"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 23,
      "product_code": "BI 3060292",
      "product_name": "NMUR2 agonist",
      "product_type": "NCE",
      "base_technology": "Peptide",
      "mechanism_of_action": "A peptide-like molecule that activates the Neuromedin U receptor 2 for treating obesity. Requires cold chain logistics.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Discontinued",
      "project_status": "Delayed",
      "lead_indication": "Obesity",
      "expected_launch_year": 2032,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "External C(D)MO"
        ],
        "DS": [
          "External C(D)MO"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 24,
      "product_code": "BI 3798489",
      "product_name": "NMUR2 agonist BU",
      "product_type": "NCE",
      "base_technology": "Peptide",
      "mechanism_of_action": "A backup unit for the Neuromedin U receptor 2 agonist program, targeting CNS appetite regulation for obesity. Requires sterile liquid formulation and SPPS.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Obesity",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "External C(D)MO"
        ],
        "DS": [
          "External C(D)MO"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 25,
      "product_code": "BI 3034701",
      "product_name": "GLP-1R/GIPR/NPY2R agonist",
      "product_type": "NBE",
      "base_technology": "Peptide",
      "mechanism_of_action": "A novel tri-agonist peptide targeting three distinct pathways for metabolic control and appetite suppression for treating obesity.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Obesity",
      "expected_launch_year": 2032,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "C(D)MO"
        ],
        "DS": [
          "C(D)MO"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 26,
      "product_code": "BI 765049",
      "product_name": "B7-H6/CD3 TCe",
      "product_type": "NBE",
      "base_technology": "BI-HEX\u00ae Platform",
      "mechanism_of_action": "A T-cell engaging bispecific antibody that links T-cells to cancer cells expressing the B7-H6 stress ligand, for treating Colorectal Cancer.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Colorectal Cancer (CRC)",
      "expected_launch_year": 2030,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Hybrid",
      "manufacturing_sites": {
        "DP": [
          "Vetter"
        ],
        "DS": [
          "Fremont"
        ]
      },
      "volume_forecast": {
        "DP": "Very Low (< 1 million PCS)",
        "DS": "Low (6 - 15 12k runs)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 27,
      "product_code": "BI 3820768",
      "product_name": "ALPG/CD3 TCe",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "An ALPG/CD3 T-cell engager for solid tumors. Requires complex protein engineering to ensure correct heavy/light chain pairing.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Solid tumors",
      "expected_launch_year": 2033,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 28,
      "product_code": "BI 3802876",
      "product_name": "FAP-TRAILR2 agonist",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "An antibody-based therapy that targets Fibroblast Activation Protein (FAP) in fibrotic tissue and activates the TRAILR2 death receptor to clear pathogenic cells.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Metabolic dysfunction-associated steatohepatitis (MASH)",
      "expected_launch_year": 2035,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 29,
      "product_code": "BI 3820923",
      "product_name": "FAP/TRAILR2 (NG) bispecific",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "A next-generation bispecific antibody targeting both FAP on tumor stromal cells and the TRAILR2 death receptor.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Metabolic dysfunction-associated steatohepatitis (MASH)",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 30,
      "product_code": "BI 836880",
      "product_name": "VEGF / ANG2 bispecific",
      "product_type": "NBE",
      "base_technology": "BI-HEX\u00ae Platform",
      "mechanism_of_action": "Dual blockade of two key pathways (VEGF / ANG2) involved in the formation of abnormal blood vessels in the eye.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Eye Health",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Wet Age-related Macular Degeneration (wAMD)",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Hybrid",
      "manufacturing_sites": {
        "DP": [
          "Vetter"
        ],
        "DS": [
          "Fremont"
        ]
      },
      "volume_forecast": {
        "DP": "Low (1 - 10 million PCS)",
        "DS": "Very Low (< 5 12k runs)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 31,
      "product_code": "BI 765179",
      "product_name": "CD137/FAP agonist AB",
      "product_type": "NBE",
      "base_technology": "BI-HEX\u00ae Platform",
      "mechanism_of_action": "A bispecific antibody that targets FAP in the tumor microenvironment while co-stimulating T-cells via the CD137 receptor, to enhance anti-tumor immunity.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "expected_launch_year": 2030,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "Biberach"
        ],
        "DS": [
          "Biberach"
        ]
      },
      "volume_forecast": {
        "DP": "Very Low (< 1 million PCS)",
        "DS": "Low (6 - 15 12k runs)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 32,
      "product_code": "BI 3706674",
      "product_name": "GDP KRAS inhibitor",
      "product_type": "NCE",
      "base_technology": "Organic Spray Drying; Roller Compaction",
      "mechanism_of_action": "A targeted therapy aimed at a specific GDP-bound form of the KRAS mutation.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Oncology",
      "current_phase": "Pre-Clinical",
      "project_status": "At Risk",
      "lead_indication": "Gastric Cancer (GC)",
      "expected_launch_year": 2029,
      "lifecycle_indications": [
        {
          "phase": "Pre-Clinical",
          "indication": "Esophageal Cancer (EC)"
        },
        {
          "phase": "Pre-Clinical",
          "indication": "GEJC"
        },
        {
          "phase": "Pre-Clinical",
          "indication": "PDAC"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "EACD Partner"
        ],
        "DS": [
          "EACD Partner"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 33,
      "product_code": "BI 765250",
      "product_name": "PD-1 agonist",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "A PD-1 agonist antibody being developed for autoimmune conditions, to be delivered via an auto-injector.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Immunology",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Systemic Sclerosis (SSc)",
      "expected_launch_year": 2033,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 34,
      "product_code": "BI 765423",
      "product_name": "anti-IL11 antibody",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "An antibody that blocks Interleukin-11, a cytokine recently identified as a critical driver of fibrotic processes in the lung and other organs. To be delivered via an auto-injector.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Respiratory",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Idiopathic/Progressive Pulmonary Fibrosis (IPF/PPFr)",
      "expected_launch_year": 2033,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 35,
      "product_code": "BI 3782253",
      "product_name": "QPCTL inhibitor",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "A small molecule inhibitor of the Glutaminyl-peptide cyclotransferase-like protein. Requires precision synthesis and formulation for lung tissue penetration.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Respiratory",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "IPF/PPFr",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 36,
      "product_code": "BI 1358894",
      "product_name": "TRPC4/5 Inhibitor",
      "product_type": "NCE",
      "base_technology": "Fluid Bed Granulation",
      "mechanism_of_action": "TRPC4/5 inhibitor targeting ion channels for mood and stress-related disorders. Requires formulation for specific CNS tissue targeting.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Mental Health",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Post-Traumatic Stress Disorder (PTSD)",
      "expected_launch_year": 2029,
      "lifecycle_indications": [
        {
          "phase": "Phase 2",
          "indication": "Major Depressive Disorder (MDD)"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "ING_SoL"
        ],
        "DS": [
          "ING",
          "Biberach Development Center"
        ]
      },
      "volume_forecast": {
        "DP": "High (>100M PCS)",
        "DS": "High (>10 tn)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 37,
      "product_code": "BI 1356225",
      "product_name": "GOAT Inhibitor",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "An inhibitor of the enzyme Ghrelin O-acyltransferase that 'activates' the hunger hormone ghrelin. Requires specialized lipophilic formulations to target the membrane-bound enzyme.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Mental Health",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Impulsivity & Substance Use Disorder (SuD)",
      "expected_launch_year": 2032,
      "lifecycle_indications": [
        {
          "phase": "Phase 1",
          "indication": "Obesity"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 38,
      "product_code": "BI 3819026",
      "product_name": "Anti-LAYN Antibody",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "An antibody targeting Layilin (LAYN) for treating solid tumors. Requires full biologics manufacturing and cold chain logistics.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Solid tumor",
      "expected_launch_year": 2033,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 39,
      "product_code": "BI 3814916",
      "product_name": "TLR4 Inhibitor",
      "product_type": "NCE",
      "base_technology": "Injectable",
      "mechanism_of_action": "Toll-like receptor 4 inhibitor. As an immunomodulator, it must be manufactured in an environment free of endotoxins to prevent unwanted immune activation.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Metabolic dysfunction-associated steatohepatitis (MASH)",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 40,
      "product_code": "BI 3821001",
      "product_name": "DcR3-Fc Fusion Protein",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "A decoy receptor (DcR3) fused to an antibody fragment (Fc) to neutralize inflammatory signals. Requires specialized Fc-fusion protein manufacturing capabilities.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Immunology",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Crohn's Disease (CD)",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 41,
      "product_code": "BI 3812465",
      "product_name": "FZD4_LRP5 Modulator",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "Targets the FZD4/LRP5 co-receptors in the Wnt signaling pathway. Manufacturing requires specialized process development for expression and purification.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Eye Health",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "CI-DME",
      "expected_launch_year": 2032,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 42,
      "product_code": "BI 1819479",
      "product_name": "ATX inhibitor",
      "product_type": "NCE",
      "base_technology": "High Shear Granulation",
      "mechanism_of_action": "An Autotaxin (ATX) inhibitor that blocks the generation of the pro-fibrotic signaling molecule LPA.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Respiratory",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Idiopathic/Progressive Pulmonary Fibrosis (IPF/PPF)",
      "expected_launch_year": 2030,
      "lifecycle_indications": [
        {
          "phase": "Pre-Clinical",
          "indication": "Systemic Sclerosis (SSc)"
        },
        {
          "phase": "Pre-Clinical",
          "indication": "Pediatric (IPF; PPF; SSc)"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "Corden"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "Medium (10 - 100 million PCS)",
        "DS": "Low (10 - 1,000 kg)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 43,
      "product_code": "BI 1820237 + Survodutide",
      "product_name": "NPY2R ago. + GCGR/GLP-1 ago. combo",
      "product_type": "NCE",
      "base_technology": "Peptide",
      "mechanism_of_action": "A combination therapy targeting multiple metabolic pathways for obesity.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Discontinued",
      "project_status": "Delayed",
      "lead_indication": "Obesity",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Hybrid",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 44,
      "product_code": "BI 3952736",
      "product_name": "KRAS G12D inhibitor",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "A targeted therapy aimed at the KRAS G12D mutation, a key driver in cancers like Pancreatic Ductal Adenocarcinoma (PDAC).",
      "dosage_form": "Tablet",
      "therapeutic_area": "Oncology",
      "current_phase": "Discontinued",
      "project_status": "Delayed",
      "lead_indication": "Pancreatic Ductal Adenocarcinoma (PDAC)",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 45,
      "product_code": "BI 685509",
      "product_name": "Avenciguat",
      "product_type": "NCE",
      "base_technology": "Direct Compression",
      "mechanism_of_action": "A soluble guanylate cyclase (sGC) activator that works by relaxing and widening blood vessels.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Immunology",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Glomerulonephritis (GN)",
      "expected_launch_year": 2028,
      "lifecycle_indications": [
        {
          "phase": "Phase 2",
          "indication": "Systemic Sclerosis (SSc)"
        },
        {
          "phase": "Phase 2",
          "indication": "Cirrhotic portal hypertension (CSPH)"
        }
      ],
      "regulatory_designations": [
        "Fast Track Designation"
      ],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "ING_SoL"
        ],
        "DS": [
          "ING"
        ]
      },
      "volume_forecast": {
        "DP": "High (>100M PCS)",
        "DS": "Medium (1 - 10 tn)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 46,
      "product_code": "BI 1839100",
      "product_name": "TRPA1 inhibitor",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "An inhibitor of the TRPA1 ion channel, which is involved in sensory nerve activation and is a key target for treating chronic cough.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Respiratory",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Chronic cough associated with IPF/PPF",
      "expected_launch_year": 2030,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "ING_SoL"
        ],
        "DS": [
          "ING"
        ]
      },
      "volume_forecast": {
        "DP": "Medium (10 - 100 million PCS)",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 47,
      "product_code": "BI 764198",
      "product_name": "TRPC6 inhibitor",
      "product_type": "NCE",
      "base_technology": "Roller Compaction",
      "mechanism_of_action": "An inhibitor of the TRPC6 ion channel, which is implicated in the pathogenesis of kidney diseases like FSGS by affecting podocyte function.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Focal Segmental Glomerulosclerosis (FSGS)",
      "expected_launch_year": 2030,
      "lifecycle_indications": [
        {
          "phase": "Pre-Clinical",
          "indication": "Duchenne Muscular Dystrophy (DMD)"
        },
        {
          "phase": "Pre-Clinical",
          "indication": "Sepsis"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Hybrid",
      "manufacturing_sites": {
        "DP": [
          "C(D)MO"
        ],
        "DS": [
          "ING"
        ]
      },
      "volume_forecast": {
        "DP": "Medium (10 - 100 million PCS)",
        "DS": "Medium (1 - 10 tn)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 48,
      "product_code": "BI 765845",
      "product_name": "MYDGF",
      "product_type": "NBE",
      "base_technology": "Microbial",
      "mechanism_of_action": "A Myeloid-derived growth factor designed to modulate the heart's response after a myocardial infarction (STEMI) to improve outcomes.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Myocardial Infarction (STEMI)",
      "expected_launch_year": 2031,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "Biberach"
        ],
        "DS": [
          "Fremont"
        ]
      },
      "volume_forecast": {
        "DP": "Very Low (< 1 million PCS)",
        "DS": "High (16 - 30 4k runs)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 49,
      "product_code": "BI 3032950",
      "product_name": "anti-TREM1",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "An antibody designed to antagonize the TREM-1 receptor on myeloid cells to dampen inflammatory responses.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Immunology",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Crohn's Disease (CD)",
      "expected_launch_year": 2035,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 50,
      "product_code": "BI 770371",
      "product_name": "SIRPa antagonist",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "An antibody that blocks the SIRP\u03b1 'don't eat me' signal receptor, intended to allow macrophages to clear pathological cells.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Metabolic dysfunction-associated steatohepatitis (MASH)",
      "expected_launch_year": 2031,
      "lifecycle_indications": [
        {
          "phase": "Phase 1",
          "indication": "Head and Neck Squamous Cell Carcinoma (HNSCC)"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "Internal"
        ],
        "DS": [
          "Internal"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 51,
      "product_code": "BI 3776528",
      "product_name": "SSTR4 agonist",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "An agonist for the Somatostatin Receptor 4, being developed to treat cognitive impairment.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Mental Health",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Cognitive Impairment Post-Stroke Depression (CI PSD)",
      "expected_launch_year": 2036,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 52,
      "product_code": "BI 3031185",
      "product_name": "mGluR4 NAM",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "A negative allosteric modulator of the mGluR4 receptor being investigated for impulsivity disorders.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Mental Health",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Impulsivity",
      "expected_launch_year": 2035,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 53,
      "product_code": "BI 1815368",
      "product_name": "PKK inhibitor",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "A Plasma Kallikrein inhibitor designed to prevent the progression to wet age-related macular degeneration.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Eye Health",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Wet AMD prevention (nAMDp)",
      "expected_launch_year": 2035,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "ING"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 54,
      "product_code": "BI 765883",
      "product_name": "TRAILR2/CDH3 AB",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "An antibody targeting both the TRAILR2 death receptor and Cadherin-3 to induce targeted apoptosis in certain cancers.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Pancreatic Ductal Adenocarcinoma (PDAC)",
      "expected_launch_year": 2033,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 55,
      "product_code": "BI 3907074/5 + BI 3720590",
      "product_name": "ATP150/152 + VSV-GP154",
      "product_type": "NBE_NTM",
      "base_technology": "Viral Vector",
      "mechanism_of_action": "A complex combination therapy involving proteins and an oncolytic virus, likely to both directly kill tumor cells and stimulate a strong immune response.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Pancreatic Ductal Adenocarcinoma (PDAC)",
      "expected_launch_year": 2034,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 56,
      "product_code": "BI 1703880",
      "product_name": "Systemic STING agonist",
      "product_type": "NCE",
      "base_technology": "Injectable",
      "mechanism_of_action": "A systemically delivered small molecule designed to activate the STING pathway throughout the body to generate a broad anti-tumor immune response.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Non-Small Cell Lung Cancer (1L squamous)",
      "expected_launch_year": 2031,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "C(D)MO"
        ],
        "DS": [
          "C(D)MO"
        ]
      },
      "volume_forecast": {
        "DP": "Very Low (< 1 million PCS)",
        "DS": "Low (10 - 1,000 kg)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 57,
      "product_code": "BI 3794407",
      "product_name": "cGAS inhibitor",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "A small molecule that blocks the cGAS enzyme, which is upstream of STING, to reduce inflammation in autoimmune diseases.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Immunology",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Systemic Sclerosis (SSc)",
      "expected_launch_year": null,
      "lifecycle_indications": [
        {
          "phase": "Pre-Clinical",
          "indication": "Interferonopathies (IFN)"
        },
        {
          "phase": "Pre-Clinical",
          "indication": "MASH"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 58,
      "product_code": "BI 3793898",
      "product_name": "mGluR3 PAM",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "A positive allosteric modulator of the mGluR3 receptor, to treat cognitive impairment.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Mental Health",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Cognitive Impairment Associated with Schizophrenia (CIAS)",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 59,
      "product_code": "BI 3000202",
      "product_name": "cGAS inhibitor",
      "product_type": "NCE",
      "base_technology": "Roller Compaction",
      "mechanism_of_action": "A small molecule that blocks the cGAS enzyme to reduce inflammation in Systemic Sclerosis.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Immunology",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Systemic Sclerosis (SSc)",
      "expected_launch_year": 2033,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "C(D)MO"
        ],
        "DS": [
          "C(D)MO"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 60,
      "product_code": "BI 1584862",
      "product_name": "PAFR antagonist",
      "product_type": "NCE",
      "base_technology": "Roller Compaction",
      "mechanism_of_action": "A platelet-activating factor receptor antagonist being investigated for Geographic Atrophy.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Eye Health",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Geographic Atrophy (GA)",
      "expected_launch_year": 2032,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "EACD Partner"
        ],
        "DS": [
          "EACD Partner"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 61,
      "product_code": "BI 3810944",
      "product_name": "ODC-IL12",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "A cytokine-based therapy combining a targeting domain (ODC) with Interleukin-12. Cytokines can be highly potent and have short half-lives, presenting unique formulation and handling challenges.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Melanoma",
      "expected_launch_year": 2033,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 62,
      "product_code": "BI 3006337",
      "product_name": "GLP-1/FGF21 agonist",
      "product_type": "NBE",
      "base_technology": "Peptide",
      "mechanism_of_action": "A dual-agonist peptide designed to activate both GLP-1 and FGF21 receptors.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Metabolic dysfunction-associated steatohepatitis (MASH)",
      "expected_launch_year": 2033,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "C(D)MO"
        ],
        "DS": [
          "C(D)MO"
        ]
      },
      "volume_forecast": {
        "DP": "Very Low (< 1 million PCS)",
        "DS": "Very Low (< 5 12k runs)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 63,
      "product_code": "BI 706321",
      "product_name": "RIPK2 inhibitor",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "RIPK2 is a kinase that plays a key role in the NOD signaling pathway, which is involved in innate immunity and inflammation.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Immunology",
      "current_phase": "Phase 2",
      "project_status": "On Track",
      "lead_indication": "Crohn's Disease (CD)",
      "expected_launch_year": 2032,
      "lifecycle_indications": [
        {
          "phase": "Pre-Clinical",
          "indication": "Crohn's Disease (CD) PED"
        }
      ],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 64,
      "product_code": "BI 765063",
      "product_name": "Oncology Agent",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "T-cell engager or similar immuno-oncology agent.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Head and Neck Squamous Cell Carcinoma (HNSCC)",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "Biberach"
        ],
        "DS": [
          "Biberach"
        ]
      },
      "volume_forecast": {
        "DP": "Very Low (< 1 million PCS)",
        "DS": "Low (6 - 15 12k runs)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 65,
      "product_code": "BI 754132",
      "product_name": "TrkB activator",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "TrkB is a receptor for brain-derived neurotrophic factor (BDNF), and activating it may have neuroprotective effects in the retina.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Eye Health",
      "current_phase": "Phase 1",
      "project_status": "On Track",
      "lead_indication": "Geographic Atrophy (GA)",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 66,
      "product_code": "BI 3018078/3024308",
      "product_name": "ATP128 + VCV-GP128",
      "product_type": "NBE_NTM",
      "base_technology": "Microbial",
      "mechanism_of_action": "Combination of an antibody/protein and an oncolytic virus.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Oncology",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Colorectal Cancer (CRC)",
      "expected_launch_year": 2032,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 67,
      "product_code": "BI 3804379",
      "product_name": "MASH Agent",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "Mechanism not specified.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Metabolic dysfunction-associated steatohepatitis (MASH)",
      "expected_launch_year": 2037,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 68,
      "product_code": "BI 3906517",
      "product_name": "LG3RA",
      "product_type": "NCE",
      "base_technology": "Solid",
      "mechanism_of_action": "Leptin receptor antagonist.",
      "dosage_form": "Tablet",
      "therapeutic_area": "Cardiovascular-Renal-Metabolic",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Obesity",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 69,
      "product_code": "BI 765243",
      "product_name": "TrkB/anti-VEGF",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "A bispecific antibody activating TrkB and inhibiting VEGF.",
      "dosage_form": "Injectable",
      "therapeutic_area": "Eye Health",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Wet AMD (nAMD)",
      "expected_launch_year": null,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "Internal",
      "manufacturing_sites": {
        "DP": [
          "tbd"
        ],
        "DS": [
          "tbd"
        ]
      },
      "volume_forecast": {
        "DP": "n/a",
        "DS": "n/a"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    },
    {
      "indications": [],
      "supply_chain": [],
      "challenges": [],
      "technologies": [],
      "product_id": 70,
      "product_code": "BI 765128",
      "product_name": "Anti-NRP1 antibody",
      "product_type": "NBE",
      "base_technology": "Mammalian",
      "mechanism_of_action": "An antibody targeting Neuropilin-1 (NRP1).",
      "dosage_form": "Injectable",
      "therapeutic_area": "Eye Health",
      "current_phase": "Pre-Clinical",
      "project_status": "On Track",
      "lead_indication": "Diabetic Retinopathy (DR)",
      "expected_launch_year": 2030,
      "lifecycle_indications": [],
      "regulatory_designations": [],
      "manufacturing_strategy": "External/Outsourced",
      "manufacturing_sites": {
        "DP": [
          "Vetter"
        ],
        "DS": [
          "Rentschler"
        ]
      },
      "volume_forecast": {
        "DP": "Very Low (< 1 million PCS)",
        "DS": "Very Low (< 5 12k runs)"
      },
      "created_at": "2025-07-15 19:43:16.527903+00:00",
      "updated_at": "2025-07-15 19:43:16.527903+00:00"
    }
  ],
  "challenges": [
    {
      "products": [],
      "challenge_id": 1,
      "challenge_category": "Containment",
      "challenge_name": "BSL-2+ Containment Facilities required",
      "explanation": "Highest biosafety classification in pharmaceutical manufacturing. For safe handling of live viral vectors (gene therapy, oncolytic viruses), special facilities with specialized air handling, waste treatment, and personnel protection are needed."
    },
    {
      "products": [],
      "challenge_id": 2,
      "challenge_category": "Containment",
      "challenge_name": "High-Potency Active Pharmaceutical Ingredient (HPAPI) Handling",
      "explanation": "Compounds with potent biological effects (e.g., immunomodulators, cytotoxics) at very low concentrations require specialized containment (e.g., OEB4, negative pressure, single-use systems) to prevent operator exposure and cross-contamination."
    },
    {
      "products": [],
      "challenge_id": 3,
      "challenge_category": "Containment",
      "challenge_name": "Low Minimum Ignition Energy (MIE) Powder Handling",
      "explanation": "Compounds with an extremely low MIE (<3 mJ) are highly sensitive to ignition from static electricity, requiring specialized safety protocols like inert atmospheres (nitrogen), explosion-proof equipment, and comprehensive static elimination measures."
    },
    {
      "products": [],
      "challenge_id": 4,
      "challenge_category": "Containment",
      "challenge_name": "Psychoactive Compound Handling",
      "explanation": "Compounds that directly affect neurotransmitter metabolism require specialized containment and controlled atmosphere processing to prevent inhalation or accidental exposure of manufacturing personnel due to their potential psychoactive properties and side effects."
    },
    {
      "products": [],
      "challenge_id": 5,
      "challenge_category": "Advanced Modality Manufacturing",
      "challenge_name": "PROTAC Manufacturing",
      "explanation": "Manufacturing Proteolysis Targeting Chimeras (PROTACs) is highly complex, involving multi-component synthesis, precise linker chemistry, and advanced purification for high molecular weight (>1000 Da) compounds that pose significant formulation and bioavailability challenges."
    },
    {
      "products": [],
      "challenge_id": 6,
      "challenge_category": "Advanced Modality Manufacturing",
      "challenge_name": "Advanced Peptide Manufacturing",
      "explanation": "Manufacturing complex peptides (e.g., multi-agonists, modified peptides) requires specialized capabilities like Solid-Phase Peptide Synthesis (SPPS), advanced purification, and precise control of stereochemistry to maintain stability and receptor selectivity."
    },
    {
      "products": [],
      "challenge_id": 7,
      "challenge_category": "Advanced Modality Manufacturing",
      "challenge_name": "Bispecific/Multi-specific Antibody Manufacturing",
      "explanation": "Manufacturing antibodies that target two or more antigens requires complex protein engineering, specialized expression systems (e.g., BI-HEX\u00ae platform) to ensure correct heavy/light chain pairing, and advanced analytics to prevent mispairing and aggregation."
    },
    {
      "products": [],
      "challenge_id": 8,
      "challenge_category": "Advanced Modality Manufacturing",
      "challenge_name": "Antibody-Drug Conjugate (ADC) Manufacturing",
      "explanation": "ADCs represent a complex dual-stream scenario, combining biologics manufacturing with HPAPI (cytotoxic payload) synthesis. This requires site-specific conjugation technologies, OEB4 containment for the payload, and advanced analytics to control the drug-to-antibody ratio (DAR)."
    },
    {
      "products": [],
      "challenge_id": 9,
      "challenge_category": "Advanced Modality Manufacturing",
      "challenge_name": "Viral Vector / Gene Therapy Manufacturing",
      "explanation": "Beyond containment, the process for viral vectors is inherently complex, requiring specialized cell culture systems for viral replication, advanced purification to separate viral particles from cell debris, and extensive viral safety testing (e.g., for RCV)."
    },
    {
      "products": [],
      "challenge_id": 10,
      "challenge_category": "Formulation & Delivery",
      "challenge_name": "Amorphous Solid Dispersion (ASD) Manufacturing",
      "explanation": "For poorly soluble compounds (BCS-IV), creating a stable amorphous solid dispersion is necessary to enhance bioavailability. This requires specialized technologies like organic spray drying, which can be complex to scale and control."
    },
    {
      "products": [],
      "challenge_id": 11,
      "challenge_category": "Formulation & Delivery",
      "challenge_name": "Device & Combination Product Manufacturing",
      "explanation": "Integrating a drug into a delivery device (e.g., a pen injector) is a major sub-project requiring close partnership with device manufacturers (e.g., Nemera), aseptic assembly, and managing the complex supply chain for a multi-component final product."
    },
    {
      "products": [],
      "challenge_id": 12,
      "challenge_category": "Formulation & Delivery",
      "challenge_name": "Formulation for Specific Tissue Targeting",
      "explanation": "For some therapies, the formulation must be specifically designed to ensure the drug penetrates and is retained in the target tissue (e.g., lungs, CNS) while minimizing systemic exposure. This requires specialized formulation development."
    },
    {
      "products": [],
      "challenge_id": 13,
      "challenge_category": "Formulation & Delivery",
      "challenge_name": "Lipophilic / Membrane-Targeted Formulation",
      "explanation": "Compounds targeting membrane-bound enzymes require specialized lipophilic formulations to ensure proper membrane partitioning and enzyme access. Maintaining the precise lipophilic-hydrophilic balance throughout manufacturing is a key challenge."
    },
    {
      "products": [],
      "challenge_id": 14,
      "challenge_category": "Formulation & Delivery",
      "challenge_name": "Cold Chain Logistics",
      "explanation": "Temperature-sensitive products like peptides, biologics, and some NCEs require a validated cold chain for storage and transportation throughout the supply chain to maintain stability and biological activity."
    },
    {
      "products": [],
      "challenge_id": 15,
      "challenge_category": "Synthesis & Purification",
      "challenge_name": "High-Selectivity Synthesis",
      "explanation": "Manufacturing compounds that inhibit one enzyme while avoiding a closely related one (e.g., >300-fold selectivity) requires high-precision synthesis with stringent control of stereochemistry. Any degradation or impurity can compromise the critical selectivity profile."
    },
    {
      "products": [],
      "challenge_id": 16,
      "challenge_category": "Synthesis & Purification",
      "challenge_name": "Covalent Inhibitor Stability",
      "explanation": "Irreversible covalent inhibitors must remain stable enough for manufacturing and storage while retaining sufficient electrophilic reactivity for therapeutic efficacy. Process development requires a careful balance to prevent premature reactions that could compromise selectivity."
    },
    {
      "products": [],
      "challenge_id": 17,
      "challenge_category": "Synthesis & Purification",
      "challenge_name": "Endotoxin-Free Manufacturing",
      "explanation": "Immunomodulatory compounds must be manufactured in an environment and with materials that are free of endotoxins to prevent unwanted and potentially dangerous immune activation in patients."
    },
    {
      "products": [],
      "challenge_id": 18,
      "challenge_category": "Synthesis & Purification",
      "challenge_name": "Complex Biologics Manufacturing",
      "explanation": "Manufacturing biologics that are not standard monoclonal antibodies (e.g., Fc-fusion proteins, complex receptor modulators) requires specialized process development for expression, purification, and analytical characterization to ensure proper structure and function."
    },
    {
      "products": [],
      "challenge_id": 19,
      "challenge_category": "Manufacturing Technology & Strategy",
      "challenge_name": "Continuous Manufacturing Implementation",
      "explanation": "Implementing continuous manufacturing technologies like Twin Screw Granulation (TSG) requires significant investment in new facilities (e.g., ING_SoL), process analytical technology (PAT), and new operational models compared to traditional batch manufacturing."
    },
    {
      "products": [],
      "challenge_id": 20,
      "challenge_category": "Manufacturing Technology & Strategy",
      "challenge_name": "Outsourced / Hybrid Supply Chain Management",
      "explanation": "Many advanced products rely on a network of external partners (C(D)MOs like Vetter, Rentschler, Lonza) for key manufacturing steps (DS, DP, device), creating a challenge in coordinating timelines, technical transfers, and quality oversight."
    }
  ]
}